9/29/2011

Onyx Pharmaceuticals has asked the FDA for priority evaluation of carfilzomib, a treatment candidate for multiple myeloma. Clinical data show that the drug reduces tumor size in patients who have received at least two previous therapies.

Full Story:
Xconomy

Related Summaries